Rajan Sharma

Rajan Sharma has more than 20 years of experience in the biotech, life sciences, and pharmaceutical industries. His vast, multi-disciplinary experience includes handling Hatch-Waxman litigation, P1V litigation, and other types of complex U.S. and international litigation.  He also has an extensive background in corporate and intellectual property law as a former General Counsel to pharmaceutical company called InnoPharma Inc., a sterile injectables company based in Piscataway, New Jersey until its acquisition by Pfizer Inc. in 2016.  He has advised a broad array of clients on litigation, corporate and intellectual property matters including licensing, corporate finance, issuance of securities and corporate governance matters.   His practice focuses in significant part on the pharmaceutical and biotech industries, but he has also represented overseas banks and tech start-ups as well. While serving as Of Counsel to LGC, he is also presently acting General Counsel to Nevakar Inc., a specialty pharmaceutical company based in Bridgewater, NJ. 

In his capacity as acting chief legal counsel of Nevakar, a company with 100 employees, he is responsible for legal oversight of all aspects of corporate governance, capital raise, stock issuance and options, business agreements with outside parties, all patent opinions and filings, and all types of litigation including intellectual property litigation as well as employee and Board matters.

Rajan also represents clients in the biotech, device and software/tech space on matters ranging from contract matters and stock option plans to mergers & acquisitions, including licensing agreements, commercial supply, co-development, marketing and/or joint ventures and corporate governance issues.

Rajan has also represented clients in numerous Hatch-Waxman litigation matters and PIV litigation, including patent counseling and opinion work, and in drafting and negotiating all types of pharmaceutical agreements (licensing, API supply and commercialization). His experience handling complex litigation also includes bondholder litigation against sovereign banks, environmental litigation in federal courts, cross-border disputes, international and consumer fraud matters at the trial and appellate levels, antitrust, RICO claims, and securities litigation, and international arbitrations, having successfully litigated claims on behalf of holders of negotiable instruments. His corporate governance experience includes securities and M&A transactions.